By Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-01-16 14:07:37
To receive our biotech newsletter and stay updated on the latest in science and politics driving biotech today, you can sign up here. We hope you had a restful and reflective long weekend. In today’s newsletter, we will be covering regulatory policy for flu vaccines and for physicians. Additionally, we have an exclusive interview with the new NIH director, Monica Bertagnolli, who shares her thoughts on finding a balance between government and industry priorities. We will also delve into the potential brain drain from a new $500 million research initiative in Kendall Square.
Monica Bertagnolli, the new director of the NIH, is grappling with conflicting priorities between President Biden’s drug pricing agenda and the goals of the broader biopharmaceutical industry. President Biden’s stance is clear: “You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” he stated last month.
For the full story on Monica Bertagnolli’s balancing act, you can continue to STAT+.
The intersection of government policy and industry priorities is a complex issue with far-reaching implications for the biotech sector. It will be interesting to see how Bertagnolli navigates these challenges in her new role.
In other news, there are concerns about a potential brain drain from the newly launched $500 million research initiative in Kendall Square. This initiative holds great promise for advancing biotech research, but there are fears that it could draw talent away from other critical areas of research.
We will continue to monitor these developments and provide you with the latest insights and analysis on the evolving landscape of biotech.
If you don’t want to miss out on any of these important updates, sign up for our biotech newsletter to have them delivered straight to your inbox. Stay informed and stay ahead in the world of biotech.
Read the original article on Africa Health News
